ClinVar Miner

Submissions for variant NM_000162.5(GCK):c.562G>A (p.Ala188Thr)

dbSNP: rs751279776
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Athena Diagnostics Inc RCV000992055 SCV001144023 pathogenic not provided 2023-09-06 criteria provided, single submitter clinical testing The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant segregates with MODY in multiple families. Assessment of experimental evidence suggests this variant results in abnormal protein function. (PMID: 8325892, 30257192)
Broad Institute Rare Disease Group, Broad Institute RCV001248939 SCV001422718 pathogenic Maturity-onset diabetes of the young type 2 2020-01-22 criteria provided, single submitter curation The p.Ala188Thr variant in GCK has been reported in 2 homozygous Egyptian individuals and 2 heterozygous Egyptian individuals with maturity-onset diabetes of the young, segregated with disease in 4 affected relatives from 1 family (DOI: 10.1007/s13410-018-0658-6), and has been identified in 0.005% (1/18390) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs751279776). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. The number of reported affected individuals with this variant is greater than expected compared to non-affected individuals with this variant. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In vitro functional studies provide some evidence that the p.Ala188Thr variant may slightly impact protein function (PMID: 30257192). However, these types of assays may not accurately represent biological function. The p.Ala188Thr variant is located in a region of GCK that is essential to protein folding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 30257192). In summary, this variant meets criteria to be classified as pathogenic for maturity-onset diabetes of the young in an autosomal dominant manner based on segregation with disease and more affected individuals with the variant than expected. ACMG/AMP Criteria applied: PP1_Strong, PM2, PS4_Moderate, PP3, PM1_Supporting, PS3_Supporting (Richards 2015).
Genetic Services Laboratory, University of Chicago RCV000992055 SCV002067433 pathogenic not provided 2020-12-08 criteria provided, single submitter clinical testing This sequence change has been previously described in multiple patients and families with GCK-related MODY (PMID: 8314448, 30257192, 14517956, 29207974 and 20337973). This particular sequence change has been described in the gnomAD database in one individual which corresponds to a population frequency of 0.00040% (dbSNP rs751279776). Experimental studies have indicated reduced enzymatic activity and protein stability for this sequence change (PMID: 30257192). The p.Ala188Thr change affects a highly conserved amino acid residue located in a Hexokinase domain of the GCK protein that is known to be functional. The p.Ala188Thr substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). These collective evidences indicate that this sequence change is pathogenic.
Geisinger Clinic, Geisinger Health System RCV001248939 SCV002562179 pathogenic Maturity-onset diabetes of the young type 2 2022-08-02 criteria provided, single submitter research PM2, PP1_Strong, PS4, PM5_Supporting, PP4, PP2, PS3
3billion RCV001248939 SCV002573171 pathogenic Maturity-onset diabetes of the young type 2 2022-09-01 criteria provided, single submitter clinical testing The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). Missense changes are a common disease-causing mechanism. Functional studies provide supporting evidence of the variant having a damaging effect on the gene or gene product (PMID: 30257192). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.93; 3Cnet: 0.97). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000804849). The variant has been reported to co-segregate with the disease in at least 3 similarly affected relatives/individuals in the same family or similarly affected unrelated families (PMID: 30257192). Different missense changes at the same codon (p.Ala188Glu, p.Ala188Gly, p.Ala188Pro, p.Ala188Val) have been reported to be associated with GCK -related disorder (ClinVar ID: VCV000036229 / PMID: 12050210 , 16965331 , 19790256 , 31968686). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline.
Invitae RCV000992055 SCV003439965 pathogenic not provided 2023-07-25 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects GCK function (PMID: 8325892, 30257192). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GCK protein function. ClinVar contains an entry for this variant (Variation ID: 804849). This missense change has been observed in individual(s) with maturity-onset diabetes of the young (PMID: 8314448, 12050210, 28170077, 30257192). It has also been observed to segregate with disease in related individuals. This variant is present in population databases (rs751279776, gnomAD 0.006%). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 188 of the GCK protein (p.Ala188Thr).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.